Spyre Therapeutics (SYRE) Institutional Ownership $29.20 -2.07 (-6.62%) (As of 11/15/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Spyre Therapeutics (NASDAQ:SYRE)CurrentInstitutional OwnershipPercentage80.39%Number ofInstitutional Buyers(last 12 months)40TotalInstitutional Inflows(last 12 months)$273.99MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$9.90M Get SYRE Insider Trade Alerts Want to know when executives and insiders are buying or selling Spyre Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SYRE Institutional Buying and Selling by Quarter Ad Genesis Gold GroupTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Spyre Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/16/2024 Geode Capital Management LLC891,048$26.21M0.0%+16.4%1.733% 11/15/2024Barclays PLC105,467$3.10M0.0%+64.7%0.205% 11/15/2024Jane Street Group LLC20,641$607K0.0%+78.7%0.040% 11/15/2024 Wellington Management Group LLP1,507,200$44.33M0.0%+89.4%2.931% 11/15/2024 State Street Corp1,541,555$45.34M0.0%+9.4%2.997% 11/15/2024 Ikarian Capital LLC302,247$8.89M1.2%N/A0.588% Get the Latest News and Ratings for SYRE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024 Janus Henderson Group PLC1,120,531$32.92M0.0%+66.3%2.179% 11/15/2024 HighVista Strategies LLC105,351$3.10M1.1%-7.2%0.205% 11/15/2024 Cinctive Capital Management LP61,256$1.80M0.1%N/A0.119% 11/14/2024 Braidwell LP2,189,836$64.40M1.8%-12.9%4.258% 11/14/2024 Walleye Capital LLC243,372$7.16M0.0%+61.4%0.473% 11/14/2024 UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC26,441$778K0.0%-12.2%0.051% 11/14/2024 MetLife Investment Management LLC20,132$592K0.0%+129.1%0.039% 11/13/2024 FMR LLC7,623,881$224.22M0.0%+1.5%14.824% 11/13/2024 The Manufacturers Life Insurance Company 43,460$1.28M0.0%+15.0%0.085% 11/12/2024 Charles Schwab Investment Management Inc.333,275$9.80M0.0%+239.4%0.655% 11/9/2024 Intech Investment Management LLC8,371$246K0.0%N/A0.016% 11/7/2024 Quest Partners LLC5,654$166K0.0%+271.2%0.011% 10/29/2024 Emerald Advisers LLC292,569$8.60M0.3%N/A0.575% 10/29/2024 Emerald Mutual Fund Advisers Trust253,550$7.46M0.4%N/A0.498% 10/23/2024 Assenagon Asset Management S.A.1,142,768$33.61M0.1%N/A2.837% 10/3/2024 SG Americas Securities LLC12,589$370K0.0%+127.0%0.031% 8/16/2024 Perceptive Advisors LLC3,031,018$71.26M1.7%+18.6%7.524% 8/16/2024 Driehaus Capital Management LLC687,080$16.15M0.2%N/A1.706% 8/15/2024 The Manufacturers Life Insurance Company37,782$888K0.0%N/A0.094% 8/15/2024 Darwin Global Management Ltd.452,040$10.27M1.2%N/A1.122% 8/15/2024 Armistice Capital LLC136,000$3.20M0.0%N/A0.338% 8/15/2024 Affinity Asset Advisors LLC513,420$12.07M1.4%N/A1.275% 8/14/2024 Great Point Partners LLC134,612$3.17M0.6%N/A0.334% 8/14/2024 Logos Global Management LP575,000$13.52M1.1%N/A1.427% 8/14/2024 Farallon Capital Management LLC666,000$15.66M0.1%N/A1.653% 8/14/2024 Integral Health Asset Management LLC100,000$2.35M0.2%N/A0.248% 8/14/2024 Avoro Capital Advisors LLC1,839,138$43.24M0.6%N/A4.566% 8/14/2024 HighVista Strategies LLC113,550$2.67M1.0%N/A0.282% 8/14/2024 Profund Advisors LLC12,606$296K0.0%N/A0.031% 8/13/2024 Ensign Peak Advisors Inc82,475$1.94M0.0%N/A0.205% 8/12/2024 Amalgamated Bank1,198$28K0.0%N/A0.003% 8/9/2024 Carlyle Group Inc.9,620$227K0.0%N/A0.024% 8/8/2024 First Turn Management LLC464,435$10.92M1.8%N/A1.153% 8/6/2024 Quest Partners LLC1,523$36K0.0%N/A0.004% How one pattern has averaged an 85% return per year since the pandemic. (Ad)Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up…8/6/2024 Candriam S.C.A.105,000$2.47M0.0%N/A0.261% 8/3/2024 TD Asset Management Inc35,168$827K0.0%N/A0.087% 8/1/2024 Rhumbline Advisers51,896$1.22M0.0%N/A0.129% 7/26/2024 Bank of New York Mellon Corp117,686$2.77M0.0%N/A0.292% 7/26/2024 EFG Asset Management North America Corp.36,781$869K0.2%N/A0.091% 7/12/2024 SG Americas Securities LLC5,545$130K0.0%N/A0.014% (Data available from 1/1/2016 forward) SYRE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SYRE shares? During the previous two years, 42 institutional investors and hedge funds held shares of Spyre Therapeutics. The most heavily invested institutionals were FMR LLC ($224.22M), Perceptive Advisors LLC ($71.26M), Braidwell LP ($64.40M), State Street Corp ($45.34M), Wellington Management Group LLP ($44.33M), Avoro Capital Advisors LLC ($43.24M), and Assenagon Asset Management S.A. ($33.61M).Learn more on SYRE's institutional investors. What percentage of Spyre Therapeutics stock is owned by institutional investors? 80.39% of Spyre Therapeutics stock is owned by institutional investors. Learn more on SYRE's institutional investor holdings. Which institutional investors have been buying Spyre Therapeutics stock? Of the 40 institutional investors that purchased Spyre Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Avoro Capital Advisors LLC ($1.84M), Assenagon Asset Management S.A. ($1.14M), Wellington Management Group LLP ($711.25K), Driehaus Capital Management LLC ($687.08K), Farallon Capital Management LLC ($666K), Logos Global Management LP ($575K), and Affinity Asset Advisors LLC ($513.42K). How much institutional buying is happening at Spyre Therapeutics? Institutional investors have bought a total of 10,650,938 shares in the last 24 months. This purchase volume represents approximately $273.99M in transactions. Which Spyre Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Spyre Therapeutics stock in the last 24 months: Braidwell LP ($324.70K), HighVista Strategies LLC ($8.20K), and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ($3.68K). How much institutional selling is happening at Spyre Therapeutics? Institutional investors have sold a total of 336,581 shares in the last 24 months. This volume of shares sold represents approximately $9.90M in transactions. Related Companies ELAN Institutional Ownership VKTX Institutional Ownership CYTK Institutional Ownership BPMC Institutional Ownership LNTH Institutional Ownership NUVL Institutional Ownership RNA Institutional Ownership ACLX Institutional Ownership KRYS Institutional Ownership ADMA Institutional Ownership This page (NASDAQ:SYRE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
